Estrogen Receptors as Therapeutic Targets in Breast Cancer

A Screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERDs)

Callis, R. J., Rabow, A. A., Tonge, M. E., Bradbury, R. H., Challinor, M., Roberts, K., Jones, K. L., & Walker, G. E. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115580298 · Cited by 29

Tools to evaluate estrogenic potency of dietary phytoestrogens:A consensus paper from the EU Thematic Network “Phytohealth” (QLKI-2002-2453)

Saarinen, N., Bingham, C., Lorenzetti, S., Mortensen, A., Mäkelä, S., Penttinen, P. E., Sørensen, I. K., Valsta, L. M., Virgili, F., Vollmer, G., et al. (2006) · Genes & Nutrition · doi:10.1007/bf02829964 · Cited by 29

ERα-targeted endocrine therapy, resistance and the role of GPER

Pepermans, R. A., & Prossnitz, E. R. (2019) · Steroids · doi:10.1016/j.steroids.2019.108493 · Cited by 32

Locating the binding sites of antitumor drug tamoxifen and its metabolites with DNA

Bourassa, P., Thomas, T., & Tajmir‐Riahi, H. A. (2014) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2014.02.028 · Cited by 28

Glutathione-responsive PROTAC for targeted degradation of ERα in breast cancer cells

Zhou, Z., Fan, H., Yu, D., Shi, F., Li, Q., Zhang, Z., Wang, X., Zhang, X., Dong, C., Sun, H., et al. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117526 · Cited by 29

Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer

Wang, Y., Min, J., Deng, X., Feng, T., Hu, H., Guo, X., Cheng, Y., Xie, B., Yang, Y., Chen, C.-C., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.005 · Cited by 28

Synergistic apoptosis of MCF-7 breast cancer cells by 2-methoxyestradiol and bis(ethyl)norspermine

Nair, S. K., Verma, A., Thomas, T., et al. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.10.027 · Cited by 27

Synthesis and structure–activity relationships of novel hybrid ferrocenyl compounds based on a bicyclic core skeleton for breast cancer therapy

Li, C., Tang, C. C., Hu, Z., Zhao, C., Li, C., Zhang, S., Dong, C., Zhou, H., & Huang, J. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.05.019 · Cited by 27

Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer

He, M., Ning, W., Hu, Z., Huang, J., Dong, C., & Zhou, H. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112281 · Cited by 33

SERMs and SERMs with estrogen for postmenopausal osteoporosis

Bolognese, M. A. (2010) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-010-9137-1 · Cited by 26

Estrogen-Related Receptor-γ Regulates Estrogen Receptor- α Responsiveness in Uterine Endometrial Cancer

Yamamoto, T., Mori, T., Sawada, M., et al. (2012) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31826fd623 · Cited by 26

Targeting steroid hormone receptors for anti‐cancer therapy—A review on small molecules and nanotherapeutic approaches

Mahadik, N. S., Bhattacharya, D., Padmanabhan, A., Sakhare, K. R., Narayan, K. P., & Banerjee‬‬‬‬‬‬‬‬‬, R. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1755 · Cited by 26

Non-Coding RNAs Modulating Estrogen Signaling and Response to Endocrine Therapy in Breast Cancer

Treeck, O., Haerteis, S., & Ortmann, O. (2023) · Cancers · doi:10.3390/cancers15061632 · Cited by 24

Bioluminescence imaging for assessment and normalization in transfected cell arrays

Pannier, A. K., Ariazi, E. A., Bellis, A. D., Bengali, Z., Jordan, V. C., & Shea, L. D. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21477 · Cited by 25

Silencing MED1 Sensitizes Breast Cancer Cells to Pure Anti-Estrogen Fulvestrant In Vitro and In Vivo

Zhang, L., Cui, J., Leonard, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070641 · Cited by 24

Navigating PROTACs in Cancer Therapy: Advancements, Challenges, and Future Horizons

Ibrahim, S., Khan, M. U., Khurram, I., Rehman, R., Rauf, A., Ahmad, Z., Aljohani, A. S. M., Abdulmonem, W. A., & Quradha, M. M. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70011 · Cited by 27

Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer

Cai, H., Li, X., Li, J., Ao, L., Yan, H., Tong, M., Guan, Q., Li, M., & Guo, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.6260 · Cited by 23

The crosstalk of the human microbiome in breast and colon cancer: A metabolomics analysis

Mukherjee, A. G., Wanjari, U. R., Bradu, P., Murali, R., Kannampuzha, S., Loganathan, T., Doss, C. G. P., Arun Prakash, B. P., Renu, K., Dey, A., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103757 · Cited by 22

Emerging principles for the development of resistance to antihormonal therapy: Implications for the clinical utility of fulvestrant

Ariazi, E. A., Lewis-Wambi, J. S., Gill, S. D., Pyle, J. R., Ariazi, J. L., Kim, H. R., Sharma, C. G. N., Cordera, F., Shupp, H. A., Li, T., et al. (2006) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2006.09.003 · Cited by 22

Identification of novel inverse agonists of estrogen-related receptors ERRγ and ERRβ

Yu, D. D., Huss, J. M., Li, H., & FORMAN, B. M. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.01.019 · Cited by 22

Design and Optimization of Oestrogen Receptor PROTACs Based on 4-Hydroxytamoxifen

Loren, G., Espuny, I., Lope, A. L., Donoghue, C., Verdaguer, X., Gomis, R. R., & Riéra, A. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114770 · Cited by 27

Downregulation of retinoblastoma protein is involved in the enhanced cytotoxicity of 4-hydroxytamoxifen plus mifepristone combination therapy versus antiestrogen monotherapy of human breast cancer

Schoenlein, P. V., Hou, M., Samaddar, J. S., et al. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.3.643 · Cited by 21

Large miRNA survival analysis reveals a prognostic four-biomarker signature for triple negative breast cancer

Andrade, F., Nakata, A., Gotoh, N., et al. (2019) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2018-0269 · Cited by 21

Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer

Luo, G., Lin, X., Ren, S., Wu, S., Wang, X., Ma, L., & Xiang, H. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113870 · Cited by 25

β-Lactam type molecular scaffolds for antiproliferative activity: Synthesis and cytotoxic effects in breast cancer cells

Meegan, M. J., Carr, M. J., Knox, A. J. S., et al. (2008) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756360802469127 · Cited by 21

Antagonistic mechanisms of bisphenol analogues on the estrogen receptor α in zebrafish embryos: Experimental and computational studies

Cao, M., Wei, J., Yu, P., Wang, L., Li, Z., Hu, Y., Liang, Y., & Cao, H. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.159259 · Cited by 22

Orphan Nuclear Receptor Errγ Induces C-Reactive Protein Gene Expression through Induction of ER-Bound Bzip Transmembrane Transcription Factor CREBH

Misra, J., Chanda, D., Kim, D.-K., Cho, S.-R., Koo, S., Lee, C. H., Back, S. H., & Choi, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086342 · Cited by 20

Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing

Ross, D. S., Zehir, A., Brogi, E., Konno, F., Krystel‐Whittemore, M., Edelweiss, M., Berger, M. F., Toy, W., Chandarlapaty, S., Razavi, P., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0116-5 · Cited by 22

In silico identification of natural products with anticancer activity using a chemo-structural database of Brazilian biodiversity

Galúcio, J. M. P., Monteiro, E. F., de Jesus, D. A., et al. (2019) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2019.107102 · Cited by 20

ApoptomiRs of Breast Cancer: Basics to Clinics

Sharma, S., Patnaik, P. K., Aronov, S., & Kulshreshtha, R. (2016) · Frontiers in Genetics · doi:10.3389/fgene.2016.00175 · Cited by 22

Intercommunication between Voltage-Gated Calcium Channels and Estrogen Receptor/Estrogen Signaling: Insights into Physiological and Pathological Conditions

Subbamanda, Y., & Bhargava, A. (2022) · Cells · doi:10.3390/cells11233850 · Cited by 18

Liposomal drug delivery systems for organ-specific cancer targeting: early promises, subsequent problems, and recent breakthroughs

Zahednezhad, F., Allahyari, S., Sarfraz, M., Zakeri‐Milani, P., Feyzizadeh, M., & Valizadeh, H. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2394611 · Cited by 20

Molecular Probes for Imaging the Sigma-2 Receptor: In Vitro and In Vivo Imaging Studies

Zeng, C., McDonald, E. S., & Mach, R. H. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_96 · Cited by 19

Chemotherapy Modulates Endocrine Therapy-Related Resistance Mutations in Metastatic Breast Cancer

Zhou, D., Ouyang, Q., Liu, L., Liu, J., Tang, Y., Xiao, M., Wang, Y., He, Q., & Hu, Z.-Y. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.02.014 · Cited by 19

A Network Pharmacology Study on the Molecular Mechanisms of FDY003 for Breast Cancer Treatment

Lee, H.-S., Lee, I.-H., Kang, K., Park, S., Moon, S.-J., Lee, C. H., & Lee, D.-Y. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/3919143 · Cited by 19

Proteomic identification of P rofilin1 as a corepressor of estrogen receptor alpha in MCF 7 breast cancer cells

Kanaujiya, J. K., Lochab, S., Kapoor, I., et al. (2013) · PROTEOMICS · doi:10.1002/pmic.201200534 · Cited by 18

HDAC3–ERα Selectively Regulates TNF-α-Induced Apoptotic Cell Death in MCF-7 Human Breast Cancer Cells via the p53 Signaling Pathway

Park, S., Kim, H., Kwak, S., Jeong, J., Lee, J., Hwang, J., Choi, H., & Choi, K. (2020) · Cells · doi:10.3390/cells9051280 · Cited by 20

Identification and characterization of estrogen receptor-related receptor alpha and gamma in human glioma and astrocytoma cells

Gandhari, M., Frazier, C. R., Hartenstein, J. S., et al. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.10.001 · Cited by 18

The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer

Capper, C. P., Larios, J. M., Sikora, M. J., Johnson, M. D., & Rae, J. M. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3774-3 · Cited by 18

Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53

Scarpetti, L., Oturkar, C. C., Juric, D., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyac281 · Cited by 17

Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen – A new hybrid design paradigm

Palermo, A. F., Diennet, M., Ezzy, M. E., Williams, B. M., Cotnoir‐White, D., Mader, S., & Gleason, J. L. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.07.026 · Cited by 19

The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1)

Najim, O., Huizing, M. T., Papadimitriou, K., et al. (2019) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2019.100123 · Cited by 17

Connecting the Missing Dots: ncRNAs as Critical Regulators of Therapeutic Susceptibility in Breast Cancer

Dobre, E.-G., Dinescu, S., & Costache, M. (2020) · Cancers · doi:10.3390/cancers12092698 · Cited by 16

PEGylated nanoassemblies composed of edelfosine and fulvestrant drugs: In vitro antiproliferative effect against breast cancer cells

Nsairat, H., Al-Sulaibi, M., & Alshaer, W. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104612 · Cited by 15

Enhanced Identification of Potential Pleiotropic Genetic Variants for Bone Mineral Density and Breast Cancer

Peng, C., Lou, H., Liu, F., Shen, J., Xu, L., Zeng, C., Long, J., Su, K., Zhang, L., Greenbaum, J., et al. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0308-x · Cited by 15

Timeless Is a Novel Estrogen Receptor Co-activator Involved in Multiple Signaling Pathways in MCF-7 Cells

Ndé, C. B. M., Gimeno, G. C., Docanto, M. M., Knower, K. C., Young, M. J., Buehn, J., Ansaar, R., & Clyne, C. D. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.03.008 · Cited by 15

A multiplex allele-specific real-time PCR assay for screening of ESR1 mutations in metastatic breast cancer

Wang, T., Liu, J., Zhang, J., Wang, L., Chen, C., & Dai, P. (2015) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2015.03.004 · Cited by 14

Identification of targets of miRNA-221 and miRNA-222 in fulvestrant-resistant breast cancer

Liu, P., Sun, M., Jiang, W., et al. (2016) · Oncology Letters · doi:10.3892/ol.2016.5180 · Cited by 14

Comparative Methods for Analysis of Protein Covalent Modification by Electrophilic Quinoids Formed from Xenobiotics

Yu, B., Qin, Z., Wijewickrama, G. T., et al. (2009) · Bioconjugate Chemistry · doi:10.1021/bc800435m · Cited by 14

Glycine soya diet synergistically enhances the suppressive effect of tamoxifen and inhibits tamoxifen-promoted hepatocarcinogenesis in 7,12-dimethylbenz[α]anthracene-induced rat mammary tumor model

Mishra, R., Bhadauria, S., Murthy, P. K., & Murthy, P. S. R. (2010) · Food and Chemical Toxicology · doi:10.1016/j.fct.2010.11.020 · Cited by 14

Unexpected equivalent potency of a constrained chromene enantiomeric pair rationalized by co-crystal structures in complex with estrogen receptor alpha

Zhang, B., Kiefer, J. R., Blake, R. A., Chang, J. H., Hartman, S. J., Ingalla, E., Kleinheinz, T., Mody, V., Nannini, M., Ortwine, D. F., et al. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.01.036 · Cited by 15

Differences in GPR30 Regulation by Chlorotriazine Herbicides in Human Breast Cells

Florian, C. P., Mansfield, S. R., & Schroeder, J. R. (2016) · Biochemistry Research International · doi:10.1155/2016/2984081 · Cited by 15

Point-activated ESR1Y541S has a dramatic effect on the development of sexually dimorphic organsPreprint

Simond, A. M., Ling, C., Moore, M. J., Condotta, S. A., Richer, M. J., & Muller, W. J. (2020) · Genes & Development · doi:10.1101/gad.339424.120 · Cited by 14

Protein-Targeted Degradation Agents Based on Natural Products

Li, Y., Jia, Y., Wang, X., Shang, H., & Tian, Y. P. (2022) · Pharmaceuticals · doi:10.3390/ph16010046 · Cited by 14

Discovery of novel 2H-chromene-3-carbonyl derivatives as selective estrogen receptor degraders (SERDs): Design, synthesis and biological evaluation

Lu, X., Teng, Y., Lin, X., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104714 · Cited by 13

Physapruin A Exerts Endoplasmic Reticulum Stress to Trigger Breast Cancer Cell Apoptosis via Oxidative Stress

Yu, T.-J., Shiau, J., Tang, J., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108853 · Cited by 13

ESR1 and endocrine therapy resistance: more than just mutations

Piscuoglio, S., Ng, C. K. Y., Weigelt, B., Chandarlapaty, S., & Reis-Filho, J. S. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy081 · Cited by 14

The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios

Ventura, L., Gnetti, L., Rossi, M., et al. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06322-z · Cited by 13

Design, docking, MD simulation and in-silco ADMET prediction studies of novel indole-based benzamides targeting estrogen receptor alfa positive for effective breast cancer therapy

Warude, B., Wagh, S. N., Chatpalliwar, V. A., Yıldırım, M., Çeli̇k, İ., Rudrapal, M., Khan, J., Chinnam, S., Garud, A., & Neharkar, V. S. (2023) · Pharmacia · doi:10.3897/pharmacia.70.e100356 · Cited by 12

Towards a New Generation of Hormone Therapies: Design, Synthesis and Biological Evaluation of Novel 1,2,3-Triazoles as Estrogen-Positive Breast Cancer Therapeutics and Non-Steroidal Aromatase Inhibitors

Rashdan, H. R. M., Abdelrahman, M. T., Luca, A. C. D., & Mangini, M. (2024) · Pharmaceuticals · doi:10.3390/ph17010088 · Cited by 11

Investigating Lasofoxifene Efficacy Against the Y537S + F404V Double-Mutant Estrogen Receptor Alpha Using Molecular Dynamics Simulations

Bouricha, E. M., & Hakmi, M. (2024) · Bioinformatics and Biology Insights · doi:10.1177/11779322241288703 · Cited by 12

Enhanced IFNα Signaling Promotes Ligand-Independent Activation of ERα to Promote Aromatase Inhibitor Resistance in Breast Cancer

Escher, T. E., Dandawate, P. R., Sayed, A. A. A., et al. (2021) · Cancers · doi:10.3390/cancers13205130 · Cited by 12

Structural optimization of tetrahydroisoquinoline-hydroxamate hybrids as potent dual ERα degraders and HDAC inhibitors

Xiong, S., Wang, X., Zhu, M., Song, K., Li, Y., Yang, J., Liu, X., Liu, M., Dong, H., Chen, M., et al. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106459 · Cited by 14

Inhibition of mammary tumor growth by estrogens: is there a specific role for estrogen receptors alpha and beta?

Soldati, R., Wargon, V., Cerliani, J. P., Giulianelli, S., Vanzulli, S. I., Gorostiaga, M. A., Bolado, J., do Campo, P., Molinolo, A., Vollmer, G., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0659-8 · Cited by 12

Integrating regression and classification-based QSARs with molecular docking analyses to explore the structure-antiaromatase activity relationships of letrozole-based analogs

Adhikari, N., Amin, S. A., Jha, T., & Gayen, S. (2017) · Canadian Journal of Chemistry · doi:10.1139/cjc-2017-0419 · Cited by 12

Bioactive Platinum(IV) Complexes Incorporating Halogenated Phenylacetates

Aputen, A. D., Elias, M. G., Gilbert, J., Sakoff, J. A., Gordon, C. P., Scott, K. F., & Aldrich-Wright, J. R. (2022) · Molecules · doi:10.3390/molecules27207120 · Cited by 12

Cationic [1,5]‐Aryl Migrations of Propargyl Benzyl Ethers – A Stereospecific Approach to E‐ and Z‐Tetrasubstituted Olefins

Sadhukhan, S., Nair, S. R., & Baire, B. (2024) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.202400030 · Cited by 11

Oestrogen receptor-mediated liposomal drug delivery for treating melanoma

Ganguly, A., Rachamalla, H. K., Bhattacharya, D., Bhamidipati, K., Pal, A. R., Ravuri, H. G., Chakravarty, S., Adhikari, S. S., & Banerjee‬‬‬‬‬‬‬‬‬, R. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1433679 · Cited by 11

Design and pharmacophoric identification of flavonoid scaffold‐based aromatase inhibitors

Banjare, L., Verma, S. K., Jain, A. K., & Thareja, S. (2020) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.4068 · Cited by 11

Hierarchical Design of Functional, Fibrous, and Microporous Polymer Monoliths for the Molecular Recognition of Diethylstilbestrol

Jeong, S., Chae, J. A., Kim, H. J., et al. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c02393 · Cited by 11

Heat shock protein90 in lobular neoplasia of the breast

Zagouri, F., Nonni, A., Sergentanis, T. Ν., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-312 · Cited by 11

Distribution Plasticity of the Human Estrogen Receptor α in Live Cells: Distinct Imaging of Consecutively Expressed Receptors

Pick, H. M., Jankevics, H., & Vogel, H. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.10.007 · Cited by 11

Synthesis of new antiproliferative 1,3,4-substituted-pyrrolo[3,2-c]quinoline derivatives, biological and in silico insights

Mingoia, F., Sano, C. D., D’Anna, C., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115537 · Cited by 10

Reduction in ERRα is associated with lichen sclerosus and vulvar squamous cell carcinoma

Lagerstedt, M., Huotari‐Orava, R., Nyberg, R. H., Maenpaa, J. U., Snellman, E., & Laasanen, S. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.10.016 · Cited by 10

Treating postmenopausal osteoporosis in women at increased risk of fracture – critical appraisal of bazedoxifene: a review

Vestergaard, & Thomsen (2009) · International Journal of Women s Health · doi:10.2147/ijwh.s5616 · Cited by 11

Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain

Sharma, A., Toy, W., Guillen, V. S., Sharma, N., Min, J., Carlson, K. E., Mayne, C. G., Lin, S., Sabio, M. L., Greene, G. L., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00877 · Cited by 10

Types of Cancers Prevailing in Pakistan and their Management Evaluation

Tariq, A., Majeed, I., & Khurshid, A. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.9.3605 · Cited by 10

Reproductive Aging of Females: Neural Systems

Brinton, R. D., Gore, A. C., Schmidt, P. J., & Morrison, J. H. (2009) · Elsevier eBooks · doi:10.1016/b978-008088783-8.00068-1 · Cited by 10

Non-EST-based prediction of novel alternatively spliced cassette exons with cell signaling function in Caenorhabditis elegans and human

Leparc, G., & Mitra, R. D. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm187 · Cited by 10

Characterization of Bizzy Nut extracts in estrogen-responsive MCF-7 breast cancer cells

Fontenot, K. R., Naragoni, S., Claville, M. O. F., et al. (2006) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2006.12.012 · Cited by 10

Anticancer Drug Conjugates Incorporating Estrogen Receptor Ligands

Zlotos, D. P., Kronenberger, T., & Laufer, S. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010067 · Cited by 9

Benzothiepin-derived molecular scaffolds for estrogen receptor modulators: synthesis and antagonistic effects in breast cancer cells

Meegan, M. J., Barrett, I., Zimmermann, J., et al. (2007) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756360701503232 · Cited by 9

The Role of Gonadotropin-Releasing-Hormone Analogues in the Treatment of Breast Cancer

Rossi, L., & Pagani, O. (2017) · Journal of Women s Health · doi:10.1089/jwh.2017.6355 · Cited by 9

Pharmacophore modeling for identification of anti-IGF-1R drugs and in-vitro validation of fulvestrant as a potential inhibitor

Khalid, S., Hanif, R., Jabeen, I., Mansoor, Q., & Ismail, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196312 · Cited by 9

Molecular Docking Analysis of Used Drugs for the Treatment of Cancer

Demirağ, A. D., Çeli̇k, S., Akyüz, S., & Özel, A. E. (2021) · Süleyman Demirel Üniversitesi Fen Bilimleri Enstitüsü Dergisi · doi:10.19113/sdufenbed.871423 · Cited by 8

Ligand- and Structure-Based Drug Design of Non-Steroidal Aromatase Inhibitors (NSAIs) in Breast Cancer

Jha, T., Adhikari, N., Halder, A. K., & Saha, A. (2015) · Advances in chemical and materials engineering book series · doi:10.4018/978-1-4666-8136-1.ch011 · Cited by 9

The Role of GPER Signaling in Carcinogenesis: A Focus on Prostate Cancer

Figueira, M. I., Cardoso, H. J., & Socorro, S. (2018) · Springer eBooks · doi:10.1007/978-3-319-71553-7_5 · Cited by 9

In-silico identification of potential inhibitors targeting the DNA binding domain of estrogen receptor α for the treatment of hormone therapy-resistant breast cancer

Bouricha, E. M., Hakmi, M., Akachar, J., Zouaidia, F., & Ibrahimi, A. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1869094 · Cited by 7

Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy

Zhao, C., Tang, C. C., Li, C., Ning, W., Hu, Z., Xin, L., Zhou, H., & Huang, J. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116185 · Cited by 11

Catalytic Cycloisomerization of Enyne Diesters Derived from Biaryls and Related Substrates

Saini, M. K., Prajapati, K., Sharma, R., et al. (2023) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.202300225 · Cited by 8

Effects of Celecoxib and Ly117018 Combination on Human Breast Cancer Cells in Vitro

Baumann, K., Klusmeier, E., Eggemann, I., et al. (2009) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s2291 · Cited by 8

Inactivation of RARβ Inhibits Wnt1-induced Mammary Tumorigenesis by Suppressing Epithelial-mesenchymal Transitions

Liu, X., & Giguère, V. (2014) · Nuclear Receptor Signaling · doi:10.1621/nrs.12004 · Cited by 8

New agents in development for breast cancer

Gao, X., & Liu, F. (2007) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e328011e6a2 · Cited by 8

Synthesis, characterization and bioactivity of new pyridine-2(H)-one, nicotinonitrile, and furo[2,3-b]pyridine derivatives

Ibrahim, M., Azmi, M. N., Alhawarri, M. B., et al. (2024) · Molecular Diversity · doi:10.1007/s11030-024-10934-5 · Cited by 7

Mechanistic evidence from classical molecular dynamics and metadynamics revealed the mechanism of resistance to 4-hydroxy tamoxifen in estrogen receptor alpha Y537S mutant

Bouricha, E. M., Hakmi, M., Kartti, S., et al. (2022) · Molecular Simulation · doi:10.1080/08927022.2022.2097283 · Cited by 7

A Screening Cascade to Identify ERβ Ligands

Filgueira, C. S., Benod, C. C., Lou, X., et al. (2014) · Nuclear Receptor Signaling · doi:10.1621/nrs.12003 · Cited by 7

Formal modeling and analysis of ER-αassociated Biological Regulatory Network in breast cancer

Khalid, S., Hanif, R., Tareen, S. H. K., Siddiqa, A., Bibi, Z., & Ahmad, J. (2016) · PeerJ · doi:10.7717/peerj.2542 · Cited by 7

Raloxifene for the treatment of postmenopausal osteoporosis

Vestergaard, P. (2012) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.12.19 · Cited by 7

Anti-hormone Therapy: Principles of Endocrine Therapy of Cancer

Hoffmann, J., & Sommer, A. (2006) · Topics in medicinal chemistry · doi:10.1007/7355_2006_002 · Cited by 7

In Silico Approaches for the Discovery of Novel Pyrazoline Benzenesulfonamide Derivatives as Anti-Breast Cancer Agents Against Estrogen Receptor Alpha (ERα)

Hasyim, D. M., Musfiroh, I., Hendra, R., Fakih, T. M., Ikram, N. K. K., & Muchtaridi, M. (2025) · Applied Sciences · doi:10.3390/app15158444 · Cited by 6

The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia

Tsourdi, E. A., Kourtis, A., Farmakiotis, D., Katsikis, I., Salmas, M., & Panidis, D. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.06.002 · Cited by 25

A Novel Strategy to Improve Women’s Health: Selective Estrogen Receptor Modulators

Abderrahman, B., & Jordan, V. C. (2018) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-99350-8_8 · Cited by 6

SERMs: current status and future trends

Morello, K. C. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(02)00022-7 · Cited by 76

Arzoxifene in postmenopausal women with normal or low bone mass

Bolognese, M. A., Krege, J. H., Utian, W. H., et al. (2009) · Bone · doi:10.1016/j.bone.2009.03.084

Selective Estrogen Receptor Modulators for Postmenopausal Osteoporosis

Gennari, L., Merlotti, D., Valleggi, F., Martini, G., & Nuti, R. (2007) · Drugs & Aging · doi:10.2165/00002512-200724050-00002 · Cited by 106